Dwight Evans is trending on Google News today, which is a strange thing to say about a congressman whose name currently returns zero news stories in the last 24 hours. The buzz is apparently coming from Bluesky, where six posts have surfaced his name, most of them about a different Dwight Evans entirely, the former Red Sox outfielder. So: a Philadelphia Democrat is going viral because baseball fans remember a right fielder from the 1980s. The internet is a strange place. But while we have your attention, Evans's financial disclosures are sitting in the public record, and they tell a mildly interesting story about a lawmaker who sold defense stock and then voted against the defense bill.
Here's What Blind Trust Knows About His Financial Record
In the last 90 days, Evans filed one disclosed stock trade: a sale of General Dynamics ($GD), somewhere between $1,001 and $15,000, executed on June 10, 2026. General Dynamics makes submarines, fighter jets, and combat systems. It's one of the five largest defense contractors in the United States. Its revenue is almost entirely dependent on government contracts, appropriations, and the annual defense authorization process that Congress runs.
Six weeks after that sale, Evans voted no on the National Defense Authorization Act for Fiscal Year 2027, the legislation that sets the Pentagon's budget and acquisition priorities for the year. The full House passed it anyway.
The trade date was June 10. The NDAA floor vote was July 22. Forty-two days. The vote-trade overlap table is empty on this one — no flagged proximity — but the calendar still earns a look.
The NDAA Vote Cluster
Evans cast a string of no votes on July 22 as the NDAA moved through the floor amendment process. He voted against the final bill. He voted against an amendment to codify chaplain protections under the Uniform Code of Military Justice, which passed anyway. He voted against an amendment that would have expanded investor access to cleared defense-sector investment opportunities, which failed. He voted against an amendment to prohibit automated speed cameras on military bases, which passed. And he voted no on an amendment requiring the Defense Secretary to produce a report on cutting 200,000 civilian Pentagon employees, which also failed.
The pattern is consistent: Evans opposed the NDAA package and most of its amendments. That's a defensible Democratic position on a Republican-drafted defense bill. Evans sits on the House Committee on Ways and Means, not Armed Services. His no votes on the NDAA don't carry a committee-oversight angle — he's not on the committee that shapes defense policy, just a member voting on the floor like every other member.
The sequence is the sequence: sold General Dynamics, voted no on the bill that funds General Dynamics's biggest customer. Evans gets to say the two facts are unrelated. He may be right.
Nine Trades. Zero Positive Alpha.
The June GD sale is the most recent trade, but the fuller picture comes from the broader alpha record Blind Trust has scored. Across nine tracked trades, Evans has produced positive 30-day alpha on exactly zero of them. The mean 30-day excess return against the S&P 500 sits at negative 5.1 percent. The best trade in the sample — a sale of American Tower ($AMT) in May — clocked in at negative 0.0 percent alpha.
The worst: a sale of Micron Technology ($MU) in March that underperformed the index by 14.1 percentage points over the following 30 days. Selling before a stock runs, while understandable from a risk-management view, is not a demonstration of market-moving information.
One trade draws a closer look. On May 7, 2026, Evans sold Thermo Fisher Scientific ($TMO), between $1,001 and $15,000. The 30-day alpha on that trade came in at negative 7.8 percent — meaning $TMO outperformed the S&P 500 by 7.8 points in the 30 days after he sold it. The committee-overlap flag is marked: Healthcare. Evans sits on the Ways and Means Health subcommittee. Thermo Fisher is a healthcare and life-sciences company whose revenue touches Medicare, Medicaid, and the federal healthcare programs that Ways and Means actually oversees.
To be precise about what the data shows: Evans sold a healthcare company on May 7. The company went on to beat the market by 7.8 percent over the next month. Evans serves on the committee that oversees healthcare spending policy. Fact pattern, not a finding. What it means is yours to decide.
A Consistent Seller Who Keeps Leaving Too Early
The broader trade history paints Evans as someone who has been selling, not buying. The alpha record covers sales of Quanta Services ($PWR), Thermo Fisher, Intel ($INTC), American Tower, and General Dynamics — all sales, no purchases in the scored sample. Every exit has underperformed on a 30-day basis, meaning the market kept going up after he left. Either Evans is a cautious, risk-averse member managing modest positions conservatively, or he has a very consistent habit of selling at the wrong time. The data doesn't choose between those interpretations.
Dollar amounts matter here. Most of these trades sit in the $1,001 to $15,000 range — the minimum disclosure bracket. Evans is not moving markets. The $MU sale reached $15,001–$50,000, the largest single position in the dataset. Still not hedge-fund money.
What Ways and Means Actually Controls
Ways and Means controls tax policy, trade, Social Security, Medicare, Medicaid, and welfare programs. Evans specifically serves on the Health and Work and Welfare subcommittees. His committee jurisdiction is genuinely relevant to healthcare stocks — Thermo Fisher, biotech companies, hospital systems, pharmacy benefit managers, anything touching federal health spending.
It is not, structurally, relevant to General Dynamics, Intel, or Quanta Services. Those companies don't sit in Ways and Means territory. The GD sale and the NDAA vote can be noted in the same article — the timing is the timing — but the committee-conflict framing only sticks to the Thermo Fisher trade. The rest are disclosures.
The Social Buzz, Such As It Is
The six Bluesky posts driving Evans's Google trend are almost entirely about the baseball player. One references a childhood affection for the Red Sox and a fond memory of the outfielder who wore number 24 for Boston from 1972 to 1991. The congressman from Pennsylvania's 3rd district is, at this moment, trending because of a Hall of Fame case for a different human being who shares his name.
Members are required to disclose their trades. They are not required to divest, recuse, or abstain. Evans's full disclosure record is on Blind Trust. His recent votes, including the full NDAA amendment cluster, are in the roll-call record. The Thermo Fisher sale with its healthcare committee overlap is flagged in the scored data. You decide if any of it's relevant to why his name is circulating today.